FCPM III SERVICES B V
Q2 2024 Form 13-F

NAARDEN
CIK 0002013410 · Institutional investment manager
Consolidated report · includes 3 managers since Q4 2023
$678.1M Reported Value Total
Reported value
$678.1M
Quarter over quarter
-10.2%
Holdings
7
Top-10 concentration
100.0%

Filing Structure

Reports holdings for

  • Forbion Growth Management B.V. (not a 13F filer in our records) · File #028-24009 · since Q4 2023
  • Forbion IV Management B.V. (not a 13F filer in our records) · File #028-24010 · since Q4 2023
  • Forbion Growth Management III B.V. (not a 13F filer in our records) · File #028-26443 · since Q1 2026 · declared by one filing
  • Forbion Growth Management III B.V. (not a 13F filer in our records) · Q4 2025 – Q4 2025 · declared by one filing
  • Forbion Growth Management II B.V. (not a 13F filer in our records) · File #028-25150 · Q1 2025 – Q3 2025 · declared by one filing
  • Forbion Growth Management II B.V. (not a 13F filer in our records) · Q4 2024 – Q4 2024 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
M.a. Van Osch And G.j. Mulder
Directors

Filing Navigation

13F Metrics

Loading 13F Metrics

Q2 2024 13F record

Q2 2024 13F filing summary

Q2 2024 Form 13F portfolio summary
Period of report June 30, 2024
Filed August 08, 2024
Form 13F-HR
Reported value $678.1M
Positions 7
Change in reported value -4.1%
New positions 1
Exited positions 0
Position turnover 14.3%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
15 $1.1B
Q2 2026 13F
Filed Aug 14, 2026
11 $750.4M
Q1 2026 13F
Filed May 15, 2026
10 $722.2M
Q4 2025 13F
Filed Feb 17, 2026
10 $762.9M
Q3 2025 13F
Filed Nov 14, 2025
9 $500.4M
Q2 2025 13F
Filed Aug 14, 2025
8 $369.2M
Q1 2025 13F
Filed May 15, 2025
7 $413.7M
Q4 2024 13F
Filed Feb 14, 2025
8 $592.4M
Q3 2024 13F
Filed Nov 14, 2024
7 $582.3M
Q2 2024 13F
Filed Aug 8, 2024
7 $678.1M
Q1 2024 13F
Filed May 3, 2024
6 $707.3M
Q4 2023 13F
Filed Mar 7, 2024
6 $339.4M

Top 7 holdings · Q2 2024

Largest Q2 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 DYN DYNE THERAPEUTICS INC $276.9M 40.83%
2 NAMS NEWAMSTERDAM PHARMA COMPANY $227.3M 33.52%
3 ENGN ENGENE HOLDINGS INC $81.8M 12.07%
4 REPL REPLIMUNE GROUP INC $43.8M 6.46%
5 BCYC BICYCLE THERAPEUTICS PLC $43.0M 6.34%
6 ENGNW ENGENE HOLDINGS INC $3.4M 0.51%
7 ACHL ACHILLES THERAPEUTICS PLC $1.9M 0.29%

Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings